Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.
Cell Reports. Medicine
Frank, Katrin J KJ; Mulero-Sánchez, Antonio A; Berninger, Alexandra A; Ruiz-Cañas, Laura L; Bosma, Astrid A; Görgülü, Kıvanç K; Wu, Nan N; Diakopoulos, Kalliope N KN; Kaya-Aksoy, Ezgi E; Ruess, Dietrich A DA; Kabacaoğlu, Derya D; Schmidt, Fränze F; Kohlmann, Larissa L; van Tellingen, Olaf O; Thijssen, Bram B; van de Ven, Marieke M; Proost, Natalie N; Kossatz, Susanne S; Weber, Wolfgang A WA; Sainz, Bruno B; Bernards, Rene R; Algül, Hana H; Lesina, Marina M; Mainardi, Sara S
Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients.
Cancers
Lallous, Nada N; Snow, Oliver O; Sanchez, Christophe C; Parra Nuñez, Ana Karla AK; Sun, Bei B; Hussain, Ahmed A; Lee, Joseph J; Morin, Helene H; Leblanc, Eric E; Gleave, Martin E ME; Cherkasov, Artem A
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS